Autologous stem cell-based cancer immunotherapy - Accurexa/StemImmuneAlternative Names: Autologous stem cell-mediated cancer therapeutic - Accurexa/StemImmune; Autologous stem cell-mediated immunotherapy - Accurexa/StemImmune
Latest Information Update: 18 Nov 2016
At a glance
- Originator StemImmune
- Class Cardiovascular therapies; Stem cell therapies
- Mechanism of Action Cell replacements; Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase I Cancer